search
Back to results

Vitamin B12, Neurodevelopment and Growth in Nepal (BeLive)

Primary Purpose

Development, Vitamin Deficiency, Malnutrition

Status
Active
Phase
Phase 2
Locations
Nepal
Study Type
Interventional
Intervention
Vitamin B12
Sponsored by
Centre For International Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Development focused on measuring Nepal, Cobalamin, Neurodevelopment, Stunting, Growth

Eligibility Criteria

6 Months - 11 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 6 to 11 months
  • Stunted
  • Availability of informed verbal consent
  • Plan to reside in the area for the next 12 months

Exclusion Criteria:

  • Severe systemic illness requiring hospitalization
  • Severe malnutrition, i.e. weight for height < -3 z of the WHO standard for this age group. For ethical reasons these children require micronutrient supplementation and adequate medical care.
  • Lack of consent
  • Taking B vitamin supplements that include vitamin B12.
  • Severe anemia (Hb < 7 g/dL). This would be a temporary exclusion and the children will be enrolled if they are successfully treated.
  • Ongoing acute infection with fever or infection that requires medical treatment. This would be a temporary exclusion and the children will be enrolled after recovery.

Sites / Locations

  • Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Vitamin B12

Placebo

Arm Description

A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)

A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)

Outcomes

Primary Outcome Measures

The Bayley Scales of Infant Development Version 3
Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), and 95% of the population has scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment; the scale is normalized on age.
Hemoglobin Concentration
Change in hemoglobin concentration from baseline to end study.

Secondary Outcome Measures

Growth Velocity Over the First Six Months of Supplementation
length and weight growth velocity z scores during supplementation z-scores, growth velocity. theoretical values -10 to 10 The higher the value, the faster the growth.
Predictors for Neurodevelopment in Young Nepali Children
Using the collected data, identify morbidity, stimulation, nutrition, socioeconomic related predictors for neurodevelopment.
Identify Subgroups of Children Who Benefit From Vitamin B12 Supplementation
Based on selected baseline variables we will identify subgroups who benefit from vitamin B12 supplementation
The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status
We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.
Neurodevelopment Measured by Other Tools.
We will measure to what extent vitamin B12 supplementation improves neurodevelopment measured by other tools such as the Ages and Stages Questionnaire (version 3) and the NEPSY II test.
Immediate Adverse Effects of the Intervention
We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.
Leucocyte Telomere Length
Relative leucocyte telomere length at end of the study period. Estimated by real-time PCR analysis
Sleep Duration
Using actigraph and a structured questionaire on all children at baseline and at end of study measure the extent to which the intervention affects sleep.

Full Information

First Posted
October 21, 2014
Last Updated
August 29, 2023
Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, NORCE Norwegian Research Centre AS
search

1. Study Identification

Unique Protocol Identification Number
NCT02272842
Brief Title
Vitamin B12, Neurodevelopment and Growth in Nepal
Acronym
BeLive
Official Title
The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 20, 2015 (Actual)
Primary Completion Date
February 28, 2018 (Actual)
Study Completion Date
December 28, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, NORCE Norwegian Research Centre AS

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Rationale: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant source of Vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and is necessary for brain growth as well as for the maintenance of its normal function. Deficiency is also associated with impaired growth. In a previous study, we demonstrated that vitamin B12 administration over a period of six months enhanced growth, and scores on a neuro-developmental test in young Indian children. However, the overall effect was small and, for the developmental scores significant only in those that were malnourished at the start of the study. Our findings need to be verified in trials targeting younger, malnourished children and with longer supplementation time. Hypothesis: This proposed study will test three hypotheses; to measure to what extent 2 recommended daily allowances (RDA) of vitamin B12 administration for one year to stunted children improves; 1) growth, 2) neurodevelopment, and 3) hemoglobin concentration. Study design: Randomized placebo-controlled trial. Half of the children will receive a paste containing vitamin B12, the other half the same paste but without vitamin B12. Study participants and site: 600 malnourished infants in Bhaktapur municipality in Nepal. In this population we have demonstrated that vitamin B12 deficiency and poor growth is common in early childhood. Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months Data: The main outcomes of this study are scores on developmental assessments tools and growth measured every month for 12 months.
Detailed Description
Scientific basis: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant source of vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and differentiation and is necessary for the development and initial myelination of the central nervous system as well as for the maintenance of its normal function. Deficiency is also associated with impaired infant and child growth. In a previous clinical trial, we demonstrated that vitamin B12 administration over a period of six months enhanced growth and neurodevelopment in young Indian children. The overall effect on growth was significant but small. We saw an effect on both ponderal (weight for age z scores) and linear (height for age z scores) growth. However, the overall effects were driven by the effects in the subgroups of children who were wasted, underweight or stunted at baseline, and no effect in the children who were not malnourished at baseline. This effect modification was significant for all three (stunting, wasting, and underweight) baseline variables. Similarly, the effect of the intervention on neurodevelopmental scores was also strongest in the subgroup of children that were stunted. We have for the last 15 years undertaken studies on dietary intake and status in women and children in Bhaktapur, Nepal. In this site, vitamin B12 deficiency is very common. The objective of the proposed study is to measure to what extent administration of 2 RDA of vitamin B12 to stunted children from the last half of infancy and for 12 months affect neurodevelopment, growth and hemoglobin concentration. Hypothesis: Daily supplementation of 2 RDA of vitamin B12 in young Nepali children for 12 months improves neurodevelopment, growth and hemoglobin concentration. Study design: Individually randomized placebo controlled, double blind trial. Children will be identified in the community and stunted children will be randomized to daily receive a paste containing vitamin B12 or a placebo paste. The paste will be delivered by trained field workers every day and by the caregivers on Saturdays and public holidays. Study participants and site: 600 stunted children aged 6 to 11 months in Bhaktapur municipality and surrounding areas. Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months. Comparator: Placebo, identical to the vitamin B12 supplements. Data: Primary outcomes: (i) neurodevelopmental scores measured by Bayley Scales of Infant and Toddler Development 3rd edition and the Ages and Stages Questionnaire 3rd edition after 6 and 12 months of supplementation (ii) growth measured by change in height for age, weight for age and weight for height z-score from study start to end study and growth velocity z scores during the six first and six last months of supplementation (iii) hemoglobin concentration after 12 months of supplementation. Secondary: (i) cognitive development in children measured approximately 3 and 6 years after enrollment, (ii) linear and ponderal growth measured 2 and 3 years after enrollment, (iii) hemoglobin concentration measured 2 and 3 years after enrollment. All secondary outcomes require additional funding. Relevance for programs and public health: Improved learning ability and growth in young malnourished children. If the supplementation is effective this will have consequences for dietary recommendation to malnourished children worldwide. In contrast to most other relevant nutritional interventions, vitamin B12 is inexpensive and our body has the ability to store vitamin B12, up to years. Thus, improving the status of this nutrient for a limited time period may have impact on learning and productivity beyond the time of administration and help to lift poor children out of the vicious cycle of poverty and malnutrition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Development, Vitamin Deficiency, Malnutrition
Keywords
Nepal, Cobalamin, Neurodevelopment, Stunting, Growth

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
600 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vitamin B12
Arm Type
Experimental
Arm Description
A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin B12
Other Intervention Name(s)
Cobalamin
Intervention Description
Vitamin B12 in a multivitamin paste.
Primary Outcome Measure Information:
Title
The Bayley Scales of Infant Development Version 3
Description
Cognitive, Fine Motor, Gross Motor, Receptive language, and Expressive language scaled scores of the Bayley Scales of Infant Development version 3. This scale measures different aspects of neurodevelopment. The mean (SD) scores are usually 100 (15), and 95% of the population has scores between 70 and 130 (theoretical max/means 0/200). The higher scores, the better neurodevelopment; the scale is normalized on age.
Time Frame
12 months
Title
Hemoglobin Concentration
Description
Change in hemoglobin concentration from baseline to end study.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Growth Velocity Over the First Six Months of Supplementation
Description
length and weight growth velocity z scores during supplementation z-scores, growth velocity. theoretical values -10 to 10 The higher the value, the faster the growth.
Time Frame
12 months
Title
Predictors for Neurodevelopment in Young Nepali Children
Description
Using the collected data, identify morbidity, stimulation, nutrition, socioeconomic related predictors for neurodevelopment.
Time Frame
12 months
Title
Identify Subgroups of Children Who Benefit From Vitamin B12 Supplementation
Description
Based on selected baseline variables we will identify subgroups who benefit from vitamin B12 supplementation
Time Frame
12 months
Title
The Effect of Vitamin B12 Supplementation on Markers of Vitamin B Status
Description
We will draw a blood sample at study start and at end study to measure to what extent vitamin status is altered.
Time Frame
12 months
Title
Neurodevelopment Measured by Other Tools.
Description
We will measure to what extent vitamin B12 supplementation improves neurodevelopment measured by other tools such as the Ages and Stages Questionnaire (version 3) and the NEPSY II test.
Time Frame
12 months
Title
Immediate Adverse Effects of the Intervention
Description
We will investigate side effects such as pain, nausea, vomiting, regurgitation, allergic reactions and others after each dose of the intervention.
Time Frame
12 months
Title
Leucocyte Telomere Length
Description
Relative leucocyte telomere length at end of the study period. Estimated by real-time PCR analysis
Time Frame
12 months
Title
Sleep Duration
Description
Using actigraph and a structured questionaire on all children at baseline and at end of study measure the extent to which the intervention affects sleep.
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Extended Followup: Neurodevelopment (IQ)
Description
Wechsler Preschool and Primary Scale of Intelligence - Fourth Edition. This is a test of general abilities ("IQ-test") Expected mean (SD): 100 (15), higher value indicate better cognitive functioning. Range approx. 40-140
Time Frame
3 years
Title
Surrogate Markers for Neurodevelopment
Description
If funding allows, measure other markers related to neurodevelopment such as Brain Derived Neurotrophic Factor
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
11 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 6 to 11 months Stunted Availability of informed verbal consent Plan to reside in the area for the next 12 months Exclusion Criteria: Severe systemic illness requiring hospitalization Severe malnutrition, i.e. weight for height < -3 z of the WHO standard for this age group. For ethical reasons these children require micronutrient supplementation and adequate medical care. Lack of consent Taking B vitamin supplements that include vitamin B12. Severe anemia (Hb < 7 g/dL). This would be a temporary exclusion and the children will be enrolled if they are successfully treated. Ongoing acute infection with fever or infection that requires medical treatment. This would be a temporary exclusion and the children will be enrolled after recovery.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prakash S Shrestha, MD
Organizational Affiliation
Tribhuvan University, Nepal
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Tor A Strand, MD/PhD
Organizational Affiliation
Innlandet Hospital Trust / University of Bergen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan
City
Bhaktapur
ZIP/Postal Code
P.O.Box 40
Country
Nepal

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data available on request. In order to meet ethical requirements for the use of confidential patient data, requests must be approved by the Nepal Health Research Council (NHRC) and the Regional Committee for Medical and Health Research Ethics in Norway. Requests for data should be sent to the authors, by contacting NHRC (http://nhrc.gov.np), or by contacting the Department of Global Health and Primary Care at the University of Bergen (post@igs.uib.no).
IPD Sharing Time Frame
Upon publication of the main outcomes.
IPD Sharing Access Criteria
The protocols and the plan of analyses will be available with the main publication. IPD will be available following an application process which involves the ethical committees in Norway and Nepal
Citations:
PubMed Identifier
23902779
Citation
Taneja S, Strand TA, Kumar T, Mahesh M, Mohan S, Manger MS, Refsum H, Yajnik CS, Bhandari N. Folic acid and vitamin B-12 supplementation and common infections in 6-30-mo-old children in India: a randomized placebo-controlled trial. Am J Clin Nutr. 2013 Sep;98(3):731-7. doi: 10.3945/ajcn.113.059592. Epub 2013 Jul 31.
Results Reference
background
PubMed Identifier
23283502
Citation
Strand TA, Taneja S, Ueland PM, Refsum H, Bahl R, Schneede J, Sommerfelt H, Bhandari N. Cobalamin and folate status predicts mental development scores in North Indian children 12-18 mo of age. Am J Clin Nutr. 2013 Feb;97(2):310-7. doi: 10.3945/ajcn.111.032268. Epub 2013 Jan 2.
Results Reference
background
PubMed Identifier
18709887
Citation
Black MM. Effects of vitamin B12 and folate deficiency on brain development in children. Food Nutr Bull. 2008 Jun;29(2 Suppl):S126-31. doi: 10.1177/15648265080292S117.
Results Reference
background
PubMed Identifier
14672291
Citation
Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr. 2003 Nov;133(11 Suppl 2):3927S-3931S. doi: 10.1093/jn/133.11.3927S.
Results Reference
background
PubMed Identifier
36138138
Citation
Chandyo RK, Schwinger C, Kvestad I, Ulak M, Ranjitkar S, Shrestha M, Nguyen LV, Corona-Perez D, DeVivo I, Shrestha L, Strand TA. The association between household biomass fuel use and leukocyte telomere length among toddlers in Bhaktapur, Nepal. J Expo Sci Environ Epidemiol. 2023 May;33(3):448-454. doi: 10.1038/s41370-022-00474-1. Epub 2022 Sep 22.
Results Reference
derived
PubMed Identifier
34999324
Citation
Hysing M, Strand TA, Chandyo RK, Ulak M, Ranjitkar S, Schwinger C, Shrestha M, Kvestad I. The effect of vitamin B12-supplementation on actigraphy measured sleep pattern; a randomized control trial. Clin Nutr. 2022 Feb;41(2):307-312. doi: 10.1016/j.clnu.2021.11.040. Epub 2021 Dec 6.
Results Reference
derived
PubMed Identifier
33259482
Citation
Strand TA, Ulak M, Hysing M, Ranjitkar S, Kvestad I, Shrestha M, Ueland PM, McCann A, Shrestha PS, Shrestha LS, Chandyo RK. Effects of vitamin B12 supplementation on neurodevelopment and growth in Nepalese Infants: A randomized controlled trial. PLoS Med. 2020 Dec 1;17(12):e1003430. doi: 10.1371/journal.pmed.1003430. eCollection 2020 Dec.
Results Reference
derived
PubMed Identifier
28431557
Citation
Strand TA, Ulak M, Chandyo RK, Kvestad I, Hysing M, Shrestha M, Basnet S, Ranjitkar S, Shrestha L, Shrestha PS. The effect of vitamin B12 supplementation in Nepalese infants on growth and development: study protocol for a randomized controlled trial. Trials. 2017 Apr 21;18(1):187. doi: 10.1186/s13063-017-1937-0.
Results Reference
derived
Links:
URL
https://www.thrasherresearch.org/SitePages/current-grants-all.aspx
Description
Link to the founding source.

Learn more about this trial

Vitamin B12, Neurodevelopment and Growth in Nepal

We'll reach out to this number within 24 hrs